New leaders appointed at the International Federation of Pharmaceutical Manufacturers & Associations
Masafumi Nogimori and Stefan Oschmann become IFPMA Acting President and Acting Vice President respectively
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) announced changes to its leadership team today. Mr. Masafumi Nogimori of Astellas Pharma Inc. becomes IFPMA Acting President while Dr. Stefan Oschmann of Merck KGaA becomes IFPMA Acting Vice President. These announcements follow the recent resignation of Mr. David Brennan, former CEO of AstraZeneca, as IFPMA President.
Mr. Nogimori is Chairman of Astellas Pharma Inc., a research-based pharmaceutical company located in Tokyo that is dedicated to improving the health of people around the world with innovative and reliable pharmaceuticals. He has served as IFPMA Vice President since 2010.
“Our industry has a long and successful record of partnering with key stakeholders around the world to address global health issues,” said Mr. Nogimori. “IFPMA is an important catalyst in these efforts and I am proud to lead this organization.”
Dr. Oschmann, Merck Executive Board Member and Chief Executive Officer of Merck Serono, brings a wealth of leadership experience to his IFPMA role. He serves along with Mr. John Lechleiter, Chairman, President and CEO of Eli Lilly and Company, who is also IFPMA Vice President.
The IFPMA Assembly will hold the next IFPMA leadership elections in October, 2012.
Geneva, 14 June 2012
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
